Moreover, when combined with RT, IR‐LND@Lip maximized T cell‐mediated tumor cell killing, possibly owing to its capability to disrupt the PD‐1/PD‐L1 recognition by inhibiting PD‐L1 expression in tumor cells, thus reinvigorating T cell‐mediated immunotherapy (Figure 2I; Figure S15, Supporting Information). Here, CD274 is linked to neoplasm.